Effect of Cannabidiol on Muscle Mass and Mitochondrial Function in Head and Neck Cancer
Key facts
- Where
- Clermont-Ferrand, FranciaországSee the 2 sites
- Phase
- 2. fázis
Where in Franciaország
- Chu Gabriel MontpiedClermont-Ferrand, FranciaországToborzás még nem indult
- University Hospital Of Clermont-FerrandClermont-Ferrand, FranciaországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Of Clermont-Ferrand
- Trial code
- EU 2024-519637-32-00
- Record updated
- 2026. január 30.
- Original description
Improvement of muscle health assessed by muscle mitochondrial activity perioperatively by adding cannabidiol (CBD) to nutritional supplementation in head and neck cancerRead full original descriptionShow less
PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial
Improvement of muscle health assessed by muscle mitochondrial activity perioperatively by adding cannabidiol (CBD) to nutritional supplementation in head and neck cancer
Inclusion: Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, larynx or prevalent lymphadenopathy) or high probability of squamous cell carcinoma of the head and neck according to the judgment of the investigator (without histological confirmation); Stage 2 or 3 nutritional risk according to the classification specific to this study (light to moderate nutritional risk); Consent to participate in the study; For women of childbearing age: absence of current pregnancy and effective contraceptive method for the duration of treatment with CBD and up to 7 days after the end of treatment; To have of a means of communication (mobile phone) to monitor tolerance and appetite while taking CBD.
Exclusion: Addiction to other drugs or cannabis; Malnutrition prior to the onset of head and neck cancer; History of severe heart failure, severe respiratory failure, severe renal failure, severe chronic obstructive pulmonary disease, uncontrolled insulin-dependent diabetes or uncontrolled coronary artery disease; History of chemotherapy or radiotherapy for head and neck cancer; History of epilepsy; Age <18 years; Pregnant and breastfeeding women; Persons under curatorship, guardianship, protection of justice or deprived of liberty; Morbid obesity; Absence of nutritional risk (grade 1) or severe nutritional risk requiring urgent renutrition (grade 4) during the nutritional assessment.